(Q36634230)

15 August 2017

1 reference

title

Adjunctive therapy with pramlintide in patients with type 1 or type 2 diabetes mellitus (English)

1 reference

15 August 2017

1 reference

Anna Nogid

1

1 reference

15 August 2017

David Q Pham

series ordinal

2

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 November 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

26

1 reference

15 August 2017

issue

11

1 reference

15 August 2017

page(s)

1626-1640

1 reference

Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1626

Clinical practice. Initial management of glycemia in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1626

Long-term complications of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1626

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1626

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1626

The medical management of hyperglycemia over a 10-year period in people with diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1626

Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second beta-cell hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1626

Amylin: a novel action in the brain to reduce body weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1626

Effects of amylin and the amylin agonist pramlintide on glucose metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1626

Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1626

Clinical implications of amylin and amylin deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1626

Pramlintide for the treatment of insulin-requiring diabetes mellitus: rationale and review of clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1626

A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1626

Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1626

Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1626

Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1626

Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1626

Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1626

Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1626

Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1626

Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. The Pramlintide in Type 2 Diabetes Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1626

By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1626

Pramlintide for the treatment of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1626

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1626

The effect of pramlintide on hormonal, metabolic or symptomatic responses to insulin-induced hypoglycaemia in patients with type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1626

Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1626

21 January 2018

Identifiers

DOI

10.1592/PHCO.26.11.1626

1 reference

15 August 2017

1 reference